allantoin has been researched along with Down Syndrome in 4 studies
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the influence of a 12-week training programme on plasmatic levels of allantoin, an in vivo marker for oxidative stress, in adolescents with Down syndrome." | 7.76 | A 12-week aerobic training programme reduced plasmatic allantoin in adolescents with Down syndrome. ( Diaz, A; Fornieles-Gonzalez, G; Ordonez, FJ; Rosety, I; Rosety, M; Rosety-Rodriguez, M, 2010) |
| "Allantoin is a nonenzymatic oxidative product of uric acid in human." | 5.32 | Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? ( Aruoma, OI; Duracková, Z; Garaiová, I; Kalnovicová, T; Korytár, P; Muchová, J; Pueschel, S; Sustrová, M; Zitnanová, I, 2004) |
| "To assess the influence of a 12-week training programme on plasmatic levels of allantoin, an in vivo marker for oxidative stress, in adolescents with Down syndrome." | 3.76 | A 12-week aerobic training programme reduced plasmatic allantoin in adolescents with Down syndrome. ( Diaz, A; Fornieles-Gonzalez, G; Ordonez, FJ; Rosety, I; Rosety, M; Rosety-Rodriguez, M, 2010) |
| "Allantoin is a nonenzymatic oxidative product of uric acid in human." | 1.32 | Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? ( Aruoma, OI; Duracková, Z; Garaiová, I; Kalnovicová, T; Korytár, P; Muchová, J; Pueschel, S; Sustrová, M; Zitnanová, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosety-Rodriguez, M | 1 |
| Rosety, I | 1 |
| Fornieles-Gonzalez, G | 1 |
| Diaz, A | 1 |
| Rosety, M | 1 |
| Ordonez, FJ | 1 |
| Tiano, L | 1 |
| Padella, L | 1 |
| Carnevali, P | 1 |
| Gabrielli, O | 1 |
| Bruge, F | 1 |
| Principi, F | 1 |
| Littarru, GP | 1 |
| Tolun, AA | 1 |
| Scarbrough, PM | 1 |
| Zhang, H | 1 |
| McKillop, JA | 1 |
| Wang, F | 1 |
| Kishnani, PS | 1 |
| Millington, DS | 1 |
| Young, SP | 1 |
| Il'yasova, D | 1 |
| Zitnanová, I | 1 |
| Korytár, P | 1 |
| Aruoma, OI | 1 |
| Sustrová, M | 1 |
| Garaiová, I | 1 |
| Muchová, J | 1 |
| Kalnovicová, T | 1 |
| Pueschel, S | 1 |
| Duracková, Z | 1 |
4 other studies available for allantoin and Down Syndrome
| Article | Year |
|---|---|
A 12-week aerobic training programme reduced plasmatic allantoin in adolescents with Down syndrome.
Topics: Adolescent; Allantoin; Case-Control Studies; Down Syndrome; Exercise; Exercise Therapy; Humans; Male | 2010 |
Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects.
Topics: Allantoin; Child; Child, Preschool; Down Syndrome; Humans; Oxidative Stress; Ubiquinone; Uric Acid | 2008 |
Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.
Topics: Adolescent; Adult; Aged; Allantoin; Biomarkers; Case-Control Studies; Child; Child, Preschool; Chrom | 2012 |
Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?
Topics: Adolescent; Aging; Allantoin; Antioxidants; Child; Chromatography, High Pressure Liquid; Down Syndro | 2004 |